teriflunomide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 14 Diseases   33 Trials   33 Trials   2608 News 


12345678910111213...3132»
  • ||||||||||  teriflunomide / Generic mfg.
    Journal:  Restless legs syndrome associated with teriflunomide use in two patients with multiple sclerosis. (Pubmed Central) -  Dec 11, 2024   
    Herein, we present two patients with MS with low Expanded Disability Status Scale scores who developed RLS symptoms shortly after starting teriflunomide and whose complaints improved immediately after discontinuing the drug. These cases emphasize the need to consider RLS as a potential side effect of teriflunomide treatment in patients with MS, in whom RLS is more common.
  • ||||||||||  glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
    Journal, IO biomarker:  Expression of STAT- and T-cell-related genes in women with first-line treatment of relapsing-remitting multiple sclerosis. (Pubmed Central) -  Dec 10, 2024   
    Expression of STAT1, STAT3, STAT5A, STAT5B, SOCS1, SOCS3, FOXP3, IKZF2, RORC and ICOS genes in the blood of untreated RRMS patients, in the blood of patients treated with interferon-?, glatiramer acetate, dimethyl fumarate or teriflunomide and in the blood of healthy controls was evaluated using droplet digital PCR...Patients treated with dimethyl fumarate also had significantly lower RORC gene expression than untreated patients. The study shows the impact of drugs used in first-line treatment of relapsing-remitting multiple sclerosis on expression of STAT and T-cell-related genes.
  • ||||||||||  brequinar (DUP 785) / BMS, Clear Creek Bio, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Journal:  Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4'-fluorouridine. (Pubmed Central) -  Dec 6, 2024   
    We propose that the impairment of endogenous uridine synthesis by DHODH inhibition enhances the incorporation of 4'-FlU into viral RNAs. This strategy may be broadly applicable to enhance the efficacy of pyrimidine nucleoside analogues for antiviral therapy.
  • ||||||||||  leflunomide / Generic mfg.
    Review, Journal:  Leflunomide nanocarriers: a new prospect of therapeutic applications. (Pubmed Central) -  Nov 28, 2024   
    Despite the aforementioned pharmacological effects exploring these effects in nanomedicine applications has been focused mainly on RA and cancer treatment. This review summarises the main pharmacological, and pharmacokinetic effects of LEF along with highlighting the applications of nanoencapsulation of LEF and its metabolite in different diseases.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Retrospective data, Journal:  Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. (Pubmed Central) -  Nov 17, 2024   
    Patients initiating heDMAs (natalizumab, alemtuzumab, and ocrelizumab) or meDMAs (interferon beta-1a, interferon beta-1b, fingolimod, teriflunomide, dimethyl fumarate, and glatiramer acetate) were included...In MS, heDMAs were associated with a greater risk of serious infection and UTI compared with meDMAs. These findings suggest the need to carefully monitor and manage the infection risk to optimize the use of heDMAs in MS.
  • ||||||||||  teriflunomide / Generic mfg.
    Journal:  Quality by design-based optimization of teriflunomide and quercetin combinational topical transferosomes for the treatment of rheumatoid arthritis. (Pubmed Central) -  Nov 16, 2024   
    The in-vivo anti-arthritic activity was evaluated in complete freund's adjuvant induced rat paw edema model illustrates the effectiveness of the combination transferosomal gel compared to other treatment groups. In conclusion, the topical delivery of TFD and QCN combination transferosomal gel demonstrated anti-arthritic activity through localized delivery allows for dose reduction, thereby may reduce the systemic drug exposure and mitigating the side effects associated with oral administration of TFD.
  • ||||||||||  decitabine / Generic mfg.
    Decitabine Activity Against TP53-Mutated Myeloid Neoplasms Is Enhanced By Combination with a Non-Cytotoxic p53/BAX-Independent Inhibitor of Pyrimidine Synthesis (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_5246;    
    DNA methyltransferase 1 (DNMT1)-degraders decitabine (Dec) or 5-azacytidine (Aza) (hypomethylating agents, HMA) with or without the BCL2-inhibitor venetoclax (Ven), are standard-of-care for TP53-mutated (m) acute myeloid leukemias (AML)...(iv) We thus considered p53/BAX-independent methods to reduce pyrimidine nucleotides : teriflunomide (Teri), approved to treat multiple sclerosis, directly inhibits de novo pyrimidine synthesis at dihydroorotate dehydrogenase (DHODH)...Conclusion. Mechanism and in vivo proof-of-principle thus support metronomic, timed-combination Teri/HMA, or Teri pro-drug leflunomide/HMA, as candidate solutions for Ven/HMA-resistance, including to treat TP53-mutated disease.
  • ||||||||||  teriflunomide / Generic mfg.
    Clinical, Journal:  Epidemiological, Clinical, and Therapeutic Profile of Uveitis in Multiple Sclerosis: A Multicenter Study. (Pubmed Central) -  Oct 25, 2024   
    MS-associated uveitis occurs most frequently before the diagnosis of relapsing-remitting MS in the form of panuveitis or intermediate uveitis, which is mildly inflammatory and whose main complications are macular edema, cataract and venous vasculitis. Despite their chronicity, these uveitis cases have a good visual prognosis and teriflunomide appears to have a positive effect on progression.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Journal:  Multiple Sclerosis-Associated Uveitis: A Case Report of Refractory Bilateral Chronic Granulomatous Panuveitis Successfully Treated with Tocilizumab. (Pubmed Central) -  Oct 25, 2024   
    A 33-year-old female patient with a history of MS inactive for 5?years on teriflunomide, and no significant medical or ophthalmological history, presented with bilateral granulomatous panuveitis...The patient underwent several lines of treatment, all of which proved unsuccessful, including corticosteroids alone or in combination with azathioprine, methotrexate, and mycophenolate mofetil...One year later, the uveitis remained inactive under a 5?mg/day prednisone regimen. Tocilizumab appears to be an efficient option for managing uveitis associated with MS and may be a valuable choice for clinicians dealing with such cases.
  • ||||||||||  teriflunomide / Generic mfg.
    Trial completion:  ULTIMS: Ultra-high-field Brain MRI in Multiple Sclerosis (clinicaltrials.gov) -  Sep 20, 2024   
    P=N/A,  N=10, Completed, 
    Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
  • ||||||||||  teriflunomide / Generic mfg.
    Observational data, Journal:  Teriflunomide, cognition and MRI: A longitudinal study. (Pubmed Central) -  Sep 12, 2024   
    Results suggest that TRF treatment in RRMS has a positive effect in cognitive function, and specifically on long term verbal memory and inhibition. Neuroimaging data suggest a link between cognition and global and focal white matter volume, particularly in the corpus callosum which is involved in anatomical disconnection syndrome and therefore brain plasticity capacities.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Clinical, Retrospective data, Review, Journal, Immunomodulating:  Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis. (Pubmed Central) -  Sep 10, 2024   
    Given the relative rarity of PMS, controlled, non-randomised studies on large samples may usefully integrate data from pivotal RCTs. Outcomes valuable and meaningful to people with PMS should be consistently adopted and measured to permit the evaluation of relative effectiveness among treatments.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
    P3 data, Journal:  Optimal patient profile for ofatumumab treatment: analysis of Russian data from the Phase 3 study (Pubmed Central) -  Aug 23, 2024   
    In a total group of 1.882 patients, a more positive effect of ofatumumab compared with teriflunomide was noted on the average annual incidence of exacerbations in men, younger people and with a mild baseline disability level - with a baseline EDSS level less than or equal to 3...This feature was also confirmed by analyzing the secondary endpoints of the study: the number of active foci on MRI and the confirmed progression of disability according to the EDSS scale. Analysis in clinical subgroups makes it possible to clarify the profile of patients in whom the greatest clinical effect can be expected when using this new drug for the treatment of MS.
  • ||||||||||  teriflunomide / Generic mfg.
    Teriflunomide Induced Dysbiosis and Colitis in a Multiple Sclerosis Patient (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_840;    
    Teriflunomide is among the few orally administered therapies available for Relapsing Remitting Multiple Sclerosis (RRMS), alongside Dimethyl fumarate, Fingolimod, etc. It is an immunomodulator recently implicated in gut microbiota dysbiosis...Her medications included Teriflunomide for MS initiated in February, along with Levetiracetam, Baclofen, Amlodipine, and Lisinopril...A diagnosis of probable C. difficile infection (CDI) was made and oral vancomycin was administered...Additionally, they reported an increasing population of Enterococci and Enterobacteriaceae, associated with C. difficile infection. This incidence supports the notion that Teriflunomide induces gut microbiota dysbiosis Figure: Ulcerations in the descending colon
  • ||||||||||  teriflunomide / Generic mfg., amisulpride / Generic mfg.
    Unusual Causes of Reversible Myoclonus: A Video Based Case Series (Poster Hall (Exhibit Hall A)) -  Aug 9, 2024 - Abstract #MDSCongress2024MDS_Congress_1643;    
    She was under therapy with amisulpride 400 mg/day for three years for a psychiatric diagnosis of depression with somatisation...Case 2: A 42-year-old lady on treatment for MS with teriflunomide 14 mg per day, presented with upper limb tremulousness for one month... Accurate identification of the etiology of a myoclonic syndrome is essential, which can expedite recovery and appropriate patient outcomes
  • ||||||||||  teriflunomide / Generic mfg., fingolimod / Generic mfg.
    Journal:  Underdosed generic specialty medications: A prescription for patient harm? (Pubmed Central) -  Jul 28, 2024   
    We analyzed 3 generic teriflunomide agents, including the one used for treatment, in addition to Aubagio?. The generic teriflunomide used by our patient contained 55.5?% content of the labeled amount, well below U.S. FDA specifications.